Table 5 Factors associated with NDPH in participants with persistent headache after COVID-19 in Latin America
From: New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study
β | p value | OR (95% confidence interval) | |
|---|---|---|---|
Age | 0.011 | 0.307 | 1.011 (0.99–1.031) |
Concomitant symptoms during the acute phase of COVID-19 | |||
Palpebral edema (reference: no) | 1.598 | 0.001 | 4.945 (1.862–13.13) |
Drooping of the upper eyelid and/or pupillary constriction (reference: no) | 1.175 | 0.111 | 3.238 (0.763–13.735) |
Sweating of the face or forehead (reference: no) | 0.325 | 0.255 | 1.385 (0.79–2.426) |
Location | |||
Occipital (reference: no) | 0.525 | 0.043 | 1.69 (1.016–2.811) |
Character | |||
Burning (reference: no) | 0.845 | 0.028 | 2.327 (1.097–4.936) |
Onset schedule (reference: during the afternoon) | |||
During the afternoon | -1.403 | 0.023 | 0.246 (0.074–0.821) |
During the evening | 0.367 | 0.436 | 1.443 (0.573–3.631) |
At any time of the day | 0.101 | 0.76 | 1.106 (0.579–2.115) |
Attenuating pain (reference: no) | -1.59 | 0.001 | 0.204 (0.078–0.536) |
Concomitant symptoms of persistent headache after COVID-19 | |||
Paresthesia (reference: no) | 0.393 | 0.158 | 1.481 (0.859–2.555) |
Mental fog (reference: no) | 0.46 | 0.087 | 1.583 (0.935–2.681) |
Nausea (reference: no) | 0.501 | 0.094 | 1.65 (0.918–2.967) |